Evidence map›Paper›PMID 28893602›Full record

ArticleAntiviral research2018

Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1

Hiromi Ogata-Aoki, Nobuyo Higashi-Kuwata, Shin-Ichiro Hattori, Hironori Hayashi, Matthew Danish, Manabu Aoki, Chiemi Shiotsu, Yumi Hashiguchi, Akinobu Hamada, Hisataka Kobayashi and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Hiromi Ogata-AokiDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nobuyo Higashi-KuwataDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Shin-Ichiro HattoriExperimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Division of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Hironori HayashiDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Matthew DanishDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan.
Manabu AokiDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
Chiemi ShiotsuDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yumi HashiguchiDepartment of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan.
Akinobu HamadaDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Hisataka KobayashiMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hironobu IhnDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Seiji OkadaDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Hiroaki MitsuyaDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Experimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. Electronic address: hmitsuya@helix.nih.gov.
Kumamoto University · JPKumamoto Health Science University · JPKumamoto University Hospital · JPNational Center for Global Health and Medicine · JPNational Institutes of Health · US

Funding

Development of Antiviral Therapy of HIV-1 InfectionZIASC006738 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 2009 to 2025
$10.0M
Activatable molecular cancer imaging probeZIABC011512 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$2.7M
HIV TRIALSZ01SC006738 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 1996 to 2008
$1.4M
Intramural NIH HHS Z01 SC006738Intramural NIH HHS ZIA BC011512
6 · The paper itself

Abstract

Employing NOD/SCID/Jak3

Indexed as

Post-Exposure ProphylaxisAnimalsAnti-HIV AgentsDisease Models, AnimalGene ExpressionGenes, ReporterGenetic VectorsHIV-1HIV InfectionsHumansImmunohistochemistryJanus Kinase 3Leukocytes, MononuclearLuminescent ProteinsMiceMice, Inbred NODAnti-HIV AgentsJanus Kinase 3Luminescent ProteinsRaltegravir PotassiumRed Fluorescent ProteinHIV-1 breakthroughIn vivo imagingmCherry-labeled HIV-1 (HIVmC)NOD/SCID/Jak3−/− (NOJ) micePost-exposure prophylaxisRaltegravir administration

Identifiers

PMID28893602
PMCPMC8057117
OpenAlexW2753653169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.